The Most-Watched Biosimilars Interviews of 2018
A number of notable guests meet The Center for Biosimilars® in 2018 to discuss important developments in this emerging field. Here are the most-watched interviews of the year.
A number of notable guests meet The Center for Biosimilars® in 2018 to discuss important developments in this emerging field. Here are the most-watched interviews of the year.
5. What Biosimilar Developers Should Know about the Rheumatic Disease Community
Seth Ginsberg, cofounder and president of the Global Healthy Living Foundation, explains how biologics have improved treatment for rheumatic diseases, and what biosimilar developers should know about the patient community that their product serve. Ginsberg calls for all stakeholders to work together to make sure that biosimilars can help patients achieve clinical benefits and cost-savings.
4. The FTC and Biosimilar Competition
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, discusses the role that the Federal Trade Commission (FTC) may play in encouraging biosimilar competition. Lassman describes the actions that the FTC has taken so far, and how the agency has played a role in clarifying questions about the Hatch-Waxman Act.
3. Using Biosimilar Filgrastim
Howard Cohen, RPh, MS, FASHP, director of oncology pharmacy services for Yale New Haven Hospital, discusses using biosimilar filgrastim. Cohen reports that his system has created an approval process for biosimilars, and has adopted Zarxio in place of Neupogen.
2. The Manufacturer’s Challenges in Getting Biosimilars to Market
Sheila Frame, vice president and head of biopharmaceuticals, North America, Sandoz, discusses the challenges that biosimilar developers face in getting their products to market. Frame highlights the roles of intellectual property disputes and policy challenges in the US market.
1. FDA and FTC Cooperation to Address Anti-Competitive Behavior
Ha Kung Wong, JD, then a partner at Fitzpatrick, Cella, Harper and Scinto, and now a partner at Venable, discusses how the FDA and FTC may work together to address anticompetitive behavior in the biosimilars marketplace. Wong highlights Risk Evaluation and Mitigation Strategies, settlements, and antitrust lawsuits as areas to watch.
